Affiliations 

  • 1 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India
  • 2 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India. Electronic address: [email protected]
  • 3 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India
  • 4 School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
  • 5 Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa
  • 6 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia
Eur J Pharmacol, 2021 Jan 05;890:173691.
PMID: 33129787 DOI: 10.1016/j.ejphar.2020.173691

Abstract

Skin diseases are the fourth leading non-fatal skin conditions that act as a burden and affect the world economy globally. This condition affects the quality of a patient's life and has a pronounced impact on both their physical and mental state. Treatment of these skin conditions with conventional approaches shows a lack of efficacy, long treatment duration, recurrence of conditions, systemic side effects, etc., due to improper drug delivery. However, these pitfalls can be overcome with the applications of nanomedicine-based approaches that provide efficient site-specific drug delivery at the target site. These nanomedicine-based strategies are evolved as potential treatment opportunities in the form of nanocarriers such as polymeric and lipidic nanocarriers, nanoemulsions along with emerging others viz. carbon nanotubes for dermatological treatment. The current review focuses on challenges faced by the existing conventional treatments along with the topical therapeutic perspective of nanocarriers in treating various skin diseases. A total of 213 articles have been reviewed and the application of different nanocarriers in treating various skin diseases has been explained in detail through case studies of previously published research works. The toxicity related aspects of nanocarriers are also discussed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.